Dr. Jennie Yanling Zheng, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 435 Doctor M Roper Pkwy N, Bullard, TX 75757 Phone: 903-894-3991 |
Dr. Gary Babbitt, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2804 Fm 2137 N, Bullard, TX 75757 Phone: 903-714-1704 |
Dr. James Harris Durrett, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 395 Highway 69 North, Bullard, TX 75757 Phone: 903-594-2450 |
Andrew Karr Bowers, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 435 Doctor M Roper Pkwy N, Bullard, TX 75757 Phone: 903-894-3991 Fax: 318-636-1416 |
News Archive
Warner Chilcott Limited has announced hat one of its subsidiaries and Mayne Pharma International Pty. Ltd. ("Mayne") have filed a second lawsuit against Impax Laboratories, Inc. ("Impax") in the District Court for the District of New Jersey for infringement of Mayne's U.S. Patent No. 6,958,161 (the "'161 Patent") which covers DORYX, a tetracycline-class oral antibiotic.
Meda has signed an agreement to acquire ZpearPoint AS, including global rights to its main product, EB24, an OTC line for treating dental erosion. Dental erosion is a common, growing condition that impacts all ages and for which there is currently no effective treatment. The condition is estimated to affect 15-50% of the population and it is sometimes referred to as the "new caries".
To enable elderly people to live at home as long as possible, a group of European researchers, coordinated from Eindhoven University of Technology, will link robots and 'smart homes'. The robot, a 'sensible family friend', will ensure that home is a nice place to stay. And that patients do the right things.
A new study published in the journal Nature attempted to investigate memory B cell evolution 5 months after vaccination with mRNA vaccines such as Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) in SARS-CoV-2 naïve individuals. The study explored various aspects of memory B cell antibody response like neutralizing response, affinity, epitope targeting, and neutralizing breadth.
Use of a patient's bone marrow cells for treating chronic ischemic heart failure did not result in improvement on most measures of heart function, according to a study appearing in JAMA. The study is being published early online to coincide with its presentation at the American College of Cardiology's annual scientific sessions.
› Verified 5 days ago